Cancer Therapeutics Cooperative Research Center

Bundoora, Australia

Cancer Therapeutics Cooperative Research Center

Bundoora, Australia
SEARCH FILTERS
Time filter
Source Type

Li R.,St. Vincent's Institute | Doherty J.,Peter MacCallum Cancer Center | Doherty J.,Cancer Therapeutics Cooperative Research Center | Antonipillai J.,St. Vincent's Institute | And 14 more authors.
Clinical and Experimental Metastasis | Year: 2013

Metastasis is the major cause of morbidity and mortality in cancer patients. An understanding of the genes that regulate metastasis and development of therapies to target these genes is needed urgently. Since members of the LIM kinase (LIMK) family are key regulators of the actin cytoskeleton and are involved in cell motility and invasion, LIMK is considered to be a good therapeutic target for metastatic disease. Here we investigated the consequences of LIMK inhibition on growth and metastasis of human and mouse mammary tumors. LIMK activity was reduced in tumor cells by expression of dominant-negative LIMK1, by RNA interference or with a selective LIMK inhibitor. The extent of phosphorylation of the LIMK substrate, cofilin, of proliferation and invasion in 2D and 3D culture and of tumor growth and metastasis in mice were assessed. Inhibition of LIMK activity efficiently reduced the pro-invasive properties of tumor cells in vitro. Tumors expressing dominant-negative LIMK1 grew more slowly and were less metastatic in mice. However, systemic administration of a LIMK inhibitor did not reduce either primary tumor growth or spontaneous metastasis. Surprisingly, metastasis to the liver was increased after administration of the inhibitor. These data raise a concern about the use of systemic LIMK inhibitors for the treatment of metastatic breast cancer. © 2012 Springer Science+Business Media Dordrecht.

Loading Cancer Therapeutics Cooperative Research Center collaborators
Loading Cancer Therapeutics Cooperative Research Center collaborators